Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15632902 | 1.00 | ALOX5 (0.49) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL15632903 | 1.00 | ALOX5 (0.49) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL2479871 | 0.83 | ALOX5 (0.50) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL15655256 | 0.81 | ALOX5 (0.49) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL15655258 | 0.81 | ALOX5 (0.49) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL28032109 | 0.80 | ALOX5 (0.47) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL9422226 | 0.77 | ALOX5 (0.45) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL960788 | 0.77 | ALOX5 (0.45) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL20741027 | 0.76 | SLC6A3 (0.44) | ALOX5TRPM8MTORMEN1KMT2A | |
| SCHEMBL20741030 | 0.76 | SLC6A3 (0.44) | ALOX5TRPM8MTORMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | ALOX5 3071/4885TRPM8 4436/4885MTOR 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.